Evolus (NASDAQ: EOLS) recently received a number of ratings updates from brokerages and research firms:
- 3/5/2018 – Evolus is now covered by analysts at Cantor Fitzgerald. They set an “overweight” rating and a $25.00 price target on the stock. They wrote, “Physicians want a less costly alternative to Allergan’s Botox. Some physicians we surveyed have been disappointed with Allergan’s consistent price increases which they are not able to pass onto patients. This creates an opportunity for Evolus which is planning to sell DWP-450 at a 20%-25% discount to Botox. Additionally, there are ~250 aesthetic KOLs who have invested in Evolus’s parent organization (Alpheon). This creates financial alignment with Evolus’s success. We also think Evolus’s KOLs are influential in the aesthetics industry and should help accelerate the adoption of DWP-450.””
- 3/5/2018 – Evolus is now covered by analysts at JMP Securities. They set an “outperform” rating and a $20.00 price target on the stock.
- 3/5/2018 – Evolus is now covered by analysts at SunTrust Banks, Inc.. They set a “buy” rating and a $24.00 price target on the stock.
- 3/5/2018 – Evolus is now covered by analysts at Mizuho. They set a “buy” rating and a $21.00 price target on the stock. They wrote, “We initiate coverage with a Buy rating and $21 PT. We expect Evolus and its low-cost toxin to carve out a niche in the attractive cash-pay cosmetic market. KeyPoints Evolus is expected to be a disruptive force in the attractive cosmetic injectable market: Evolus is an aesthetics-focused company that plans to launch its injectable toxin in 2018. Evolus’ toxin, unlike other players in the U.S. market, is distinguished by its interchangeability with Botox and by the company’s willingness to offer meaningful discounts to physicians and/ or patients. Evolus will therefore effectively introduce a promoted Botox Cosmetic branded generic” years ahead of any biosimilar product, and we expect its toxin to help with overall market access to younger or cost- sensitive patients. We think Evolus could carve out an attractive niche in this space and valuation is attractive even under extremely conservative launch assumptions. We initiate with a Buy rating and $21 PT.””
Evolus Inc (EOLS) traded up $0.30 during mid-day trading on Monday, hitting $12.37. 216,573 shares of the stock were exchanged, compared to its average volume of 132,240. Evolus Inc has a twelve month low of $9.60 and a twelve month high of $12.97.
Evolus, Inc is a medical aesthetics company. The Company is focused on providing physicians and aesthetic procedures and treatments. It also focuses on offering the self-pay aesthetic market and its product candidate, PrabotulinumtoxinA (DWP-450), is an injectable 900 kilodalton, or kDa, botulinum toxin type designed to address the needs of the large and growing facial aesthetics market.
Receive News & Ratings for Evolus Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus Inc and related companies with MarketBeat.com's FREE daily email newsletter.